Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial compared two long-acting insulin products — HOE901-U300 (also known as insulin glargine 300 units/mL) and Lantus (insulin glargine 100 units/mL) — in people with diabetes. A total of 1,014 participants were enrolled (508 in the HOE901-U300 group and 506 in the Lantus group), and the trial ran for 26 weeks. The main thing being measured was the change in a blood sugar marker called HbA1c — a percentage figure that reflects average blood sugar levels over roughly three months — from the start of the trial to week 26. The reported data shows that, on average, HbA1c fell by 0.89 percentage points in the HOE901-U300 group and by 0.91 percentage points in the Lantus group over the 26 weeks. For the secondary outcomes, the trial also tracked how many participants experienced episodes of low blood sugar (hypoglycaemia — when blood sugar drops to a potentially harmful level). During the full 26-week period, roughly 48.3% of the HOE901-U300 group and 47.7% of the Lantus group were reported to have had at least one low blood sugar episode overnight (between 10 pm and 9 am). In the narrower overnight window of midnight to 6 am, the reported figures were 20.2% and 22.5% respectively. For low blood sugar episodes at any time of day, the reported figures were 59.4% (HOE901-U300) and 62.7% (Lantus). The trial also measured how many participants reached an HbA1c below 7.5% or below 7.0%, and how many reached those targets without also having a low blood sugar episode — the numbers for each of those measures are included in the data submitted to ClinicalTrials.gov. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 29895556) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Type 2 Diabetes Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You are 65 years old or older and have been diagnosed with type 2 diabetes that is not well controlled by your current diabetes medications
- Your current diabetes treatment includes either no insulin at all, or only a long-acting (basal) insulin as your only insulin type
- You have agreed to take part and signed a consent form
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- Your blood sugar control level (HbA1c) is either too low or too high at the screening visit — the exact acceptable range depends on whether you currently use insulin (confirm with trial site)
- You have had type 2 diabetes for less than one year before the screening visit
- Your long-acting insulin dose has changed by more than 10% in the last 8 weeks before the screening visit
- Your diabetes medication doses have been changed, or a new blood sugar medication was started, in the last 8 weeks before the screening visit
- You have used short-acting (bolus) insulin injections regularly for more than 10 days in a row during the past 6 months, or — if you have never used insulin — you have used any insulin for more than 10 days in a row in the past year (except for a short-term situation like illness or surgery)
- You have been diagnosed with dementia or significant memory/thinking problems, or a neurological condition that might affect your ability to follow the study procedures (confirm with trial site)
- You have severe kidney disease, meaning your kidneys are functioning at a very low level (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Principal Investigator: Clinical Sciences & Operations, Sanofi
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 4 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Change in HbA1c From Baseline to Week 26
Other options
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.